Valneva SE (VALN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
VALN currently has 174M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 6.86% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 17, 2026 |
20-F filing | 173.5M shares outstanding |
170M | 0 |
| Mar 25, 2025 |
F-3 filing: Valneva SE files an F-3 registration statement to offer ordinary shares, ADSs, and warrants up to $350,000,000, including an ATM offering of ADSs through Jefferies LLC up to $75,000,000. |
160M | 0 |
| Mar 24, 2025 |
20-F filing | 162.5M shares outstanding |
160M | 0 |
| Mar 22, 2024 |
20-F filing | 138.9M shares outstanding |
140M | 0 |
| Mar 30, 2023 |
20-F filing | 138.4M shares outstanding |
140M | 0 |
| Aug 12, 2022 |
F-3 filing: The filing is for a shelf offering of up to $200,000,000 of ordinary shares, including ordinary shares represented by American Depositary Shares, or ADSs, as well as warrants to purchase ordinary shares or ADSs. |
120M | 0 |
| Mar 24, 2022 |
20-F filing | 105.2M shares outstanding |
110M | 0 |
| Oct 26, 2021 |
F-1 filing: This is an F-1 filing for a global offering of ordinary shares and ADSs. Legal representation is provided by Cooley LLP and Goodwin Procter LLP. |
91M | 0 |
| Apr 09, 2021 |
F-1 filing: This F-1 filing relates to a global offering of ordinary shares (including ordinary shares in the form of ADSs). The underwriters have an option to purchase additional ordinary shares. The company intends to use the net proceeds to fund further development of its Lyme, chikungunya and COVID-19 vaccine candidates, to advance pre-clinical vaccine candidate programs and for working capital and general corporate purposes. |
91M | 0 |